Dietary Fat, Eicosanoids and Breast Cancer Risk

NCT ID: NCT01824498

Last Updated: 2018-08-31

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-01-31

Study Completion Date

2010-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this investigation is to determine whether diets designed to increase plasma n3 concentrations (a low fat diet, with or without n3 fatty acid enrichment), will favorably affect sex hormone distribution in women in a direction associated with reduced risk of sex hormone-mediated cancer development. Specifically, we hypothesize that an increased concentration of circulating n3 fatty acids will reduce the biochemical markers associated with increased risk for developing certain sex hormone mediated cancers such as breast cancer

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The guiding concept of our proposal is that both the total fat and the fatty acid composition of the diet contribute to a milieu associated with the risk for sex-hormone mediated cancers. Specifically, we hypothesize that an increased concentration of circulating n3 fatty acids will reduce the biochemical markers associated with increased risk for developing certain sex hormone mediated cancers such as breast cancer. When compared with the high fat diet, we expect n3 concentrations to increase and sex hormone levels to decrease after both low fat and low fat/n3 rich diets, with the greatest response in the low fat-n3 supplemented group. The aims of this project are: 1) to evaluate the effects of total fat and n3 fatty acid consumption on plasma and urine sex hormone concentrations in postmenopausal women, 2) to evaluate the relationship between plasma concentrations of fatty acids and plasma and urinary sex hormone concentrations, and 3) to evaluate the effects of total fat and n3 fatty acid consumption on the associations between sex hormone concentrations and urinary prostaglandin E2 and thromboxane B2 concentrations.

The primary objective of this investigation is to determine whether diets designed to increase plasma n3 concentrations (a low fat diet, with or without n3 fatty acid enrichment), will favorably affect sex hormone distribution in women in a direction associated with reduced risk of sex hormone-mediated cancer development. The primary endpoints to be evaluated include plasma and urinary sex hormone concentrations as follows:

Endpoints associates with increased risk factors for breast cancer risk: plasma estradiol (E2), estrone (E1), estrone sulfate (E1 sulfate), testosterone, androstenedione, sex hormone binding globulin (SHBG), dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS), Measures of estrogen action: plasma follicle stimulating hormone (FSH), urinary estrogen metabolites.

Measures of systemic arachidonic acid-derived eicosanoids: urinary bicyclo-prostaglandin E2 (PGEa), 2,3-dinor thromboxane B2 (TXB2).

Measures reflecting influence of dietary fat and fatty acid intake: plasma phospholipid, cholesterol ester, triglyceride and free fatty acid composition.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low Fat, High Fat, Low Fat High Omega 3

See Intervention Description

Group Type EXPERIMENTAL

Low Fat diet

Intervention Type OTHER

Low fat diet = 20% fat

Low Fat high n3 diet

Intervention Type OTHER

Low Fat high n3 diet = 20% fat + 3% n3

High Fat Diet

Intervention Type OTHER

High Fat Diet = 40% fat

Low Fat, Low Fat High Omega 3, High Fat

See Intervention Description

Group Type EXPERIMENTAL

Low Fat diet

Intervention Type OTHER

Low fat diet = 20% fat

Low Fat high n3 diet

Intervention Type OTHER

Low Fat high n3 diet = 20% fat + 3% n3

High Fat Diet

Intervention Type OTHER

High Fat Diet = 40% fat

High Fat, Low Fat, Low Fat High Omega 3

See Intervention Description

Group Type EXPERIMENTAL

Low Fat diet

Intervention Type OTHER

Low fat diet = 20% fat

Low Fat high n3 diet

Intervention Type OTHER

Low Fat high n3 diet = 20% fat + 3% n3

High Fat Diet

Intervention Type OTHER

High Fat Diet = 40% fat

High Fat, Low fat High Omega 3, Low Fat

See Intervention Description

Group Type EXPERIMENTAL

Low Fat diet

Intervention Type OTHER

Low fat diet = 20% fat

Low Fat high n3 diet

Intervention Type OTHER

Low Fat high n3 diet = 20% fat + 3% n3

High Fat Diet

Intervention Type OTHER

High Fat Diet = 40% fat

Low Fat High Omega 3, High Fat, Low Fat

See Intervention Description

Group Type EXPERIMENTAL

Low Fat diet

Intervention Type OTHER

Low fat diet = 20% fat

Low Fat high n3 diet

Intervention Type OTHER

Low Fat high n3 diet = 20% fat + 3% n3

High Fat Diet

Intervention Type OTHER

High Fat Diet = 40% fat

Low Fat High Omega 3, Low Fat, High Fat

See Intervention Description

Group Type EXPERIMENTAL

Low Fat diet

Intervention Type OTHER

Low fat diet = 20% fat

Low Fat high n3 diet

Intervention Type OTHER

Low Fat high n3 diet = 20% fat + 3% n3

High Fat Diet

Intervention Type OTHER

High Fat Diet = 40% fat

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Low Fat diet

Low fat diet = 20% fat

Intervention Type OTHER

Low Fat high n3 diet

Low Fat high n3 diet = 20% fat + 3% n3

Intervention Type OTHER

High Fat Diet

High Fat Diet = 40% fat

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Postmenopausal women
* 45 to 70 years old,
* at least one year since their last menstrual period
* not using hormone replacement therapy,
* BMI between 19 -29
* willingness to discontinue use of over-the-counter medications with anti-prostaglandin activity such as aspirin or non-steroidal anti-inflammatory medications
* consumption of a "Typical " American diet with no unusual dietary practices such as compliance with a strict vegetarian diet
* willingness to comply with the demands of the experimental protocol.

Exclusion Criteria

* Smoking
* Known disease process, and 3) Use of prescription medications, including hormone replacement therapy.
Minimum Eligible Age

40 Years

Maximum Eligible Age

70 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

USDA Grand Forks Human Nutrition Research Center

FED

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Susan K Raatz, PhD, RD

Role: PRINCIPAL_INVESTIGATOR

USDA, GFHNRC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Minnesota

Minneapolis, Minnesota, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

McColley SP, Georgopoulos A, Young LR, Kurzer MS, Redmon JB, Raatz SK. A high-fat diet and the threonine-encoding allele (Thr54) polymorphism of fatty acid-binding protein 2 reduce plasma triglyceride-rich lipoproteins. Nutr Res. 2011 Jul;31(7):503-8. doi: 10.1016/j.nutres.2011.06.003.

Reference Type BACKGROUND
PMID: 21840466 (View on PubMed)

Raatz SK, Young LR, Picklo MJ Sr, Sauter ER, Qin W, Kurzer MS. Total dietary fat and fatty acid content modifies plasma phospholipid fatty acids, desaturase activity indices, and urinary prostaglandin E in women. Nutr Res. 2012 Jan;32(1):1-7. doi: 10.1016/j.nutres.2011.12.006.

Reference Type BACKGROUND
PMID: 22260857 (View on PubMed)

Young LR, Raatz SK, Thomas W, Redmon JB, Kurzer MS. Total dietary fat and omega-3 fatty acids have modest effects on urinary sex hormones in postmenopausal women. Nutr Metab (Lond). 2013 Apr 23;10(1):36. doi: 10.1186/1743-7075-10-36.

Reference Type BACKGROUND
PMID: 23618064 (View on PubMed)

Young LR, Kurzer MS, Thomas W, Redmon JB, Raatz SK. Effect of dietary fat and omega-3 fatty acids on urinary eicosanoids and sex hormone concentrations in postmenopausal women: a randomized controlled feeding trial. Nutr Cancer. 2011;63(6):930-9. doi: 10.1080/01635581.2011.589957. Epub 2011 Jul 11.

Reference Type RESULT
PMID: 21745038 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UMN914

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.